FDA Rejects Merck's 6-Week Dosing Schedule for Keytruda
Astellas and Seattle Genetics Win Accelerated Approval for Bladder Cancer Drug
Merck's Keytruda is bound for new bladder cancer territory. But can it hold up against gene therapy?
Merck’s Keytruda: A Deep Dive
5 questions ESMO cancer drug data might answer
Roche's Tecentriq scores solo win in lung cancer. But can it challenge Merck's Keytruda?
Roche's Tecentriq, on an EU hot streak, bags 2 new lung cancer approvals
Keytruda Approvals: A Timeline
AstraZeneca’s Imfinzi tees up small cell lung cancer fight with Roche
FDA Gives Merck's Keytruda Thumbs-Up for Two More Indications